银化物Rb1通过SIRT1/PGC-1α和PI3K/AKT通路调节线粒体功能障碍来缓解喘炎症
Huiwen Li1,2, Ying Piao2,3, Qiaoyun Bai2,4
1Department of Neonatology, Affiliated Hospital of Yanbian University, Yanji 133000, P. R. China.
Biological & pharmaceutical bulletin
|November 16, 2025
概括
金色化物Rb1通过保护线粒体,有效治疗喘. 这种天然化合物减少了炎症和氧化应激,为呼吸系统疾病提供了潜在的治疗方法.
科学领域:
- 生物化学 生化学
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 喘是一种慢性呼吸道疾病,其特点是气道炎症.
- 线粒体功能障碍在喘的发病过程中起着重要作用.
- 提取物 (CRE) 是一种常见的过敏原,会引起类似喘的症状.
研究的目的:
- 为了研究金氏化物Rb1对CRE诱导的喘的保护作用.
- 阐明Rb1的作用背后的机制,重点关注线粒体功能和相关的信号通路.
主要方法:
- 在CRE诱导的喘动物模型中,使用不同剂量的金氏化物Rb1.1.进行治疗.
- 组织病理学分析 (H&E染色),免疫试验 (ELISA) 和流细胞计用于评估炎症.
- 西方斑点,TUNEL和免疫光测试被用于评估氧化应激,亡和线粒体动态.
- 还在BEAS-2B细胞中进行了实验,以确认细胞机制.
主要成果:
- 银化物Rb1显著降低了喘小鼠的炎症细胞透,IgE水平和炎症细胞因子.
- Rb1通过调节抗氧化酶和甲水平来抑制氧化应激.
- 观察到SIRT1/PGC-1α通路的激活和PI3K/AKT通路的抑制.
- Rb1促进了线粒体融合 (MFN1) 和抑制了裂变 (DRP1),减少了亡并改善了线粒体功能.
结论:
- 银化物Rb1通过维持线粒体完整性来改善喘性气道炎症.
- 治疗效果包括SIRT1/PGC-1α的激活和PI3K/AKT信号通路的抑制.
- 通过准线粒体功能障碍,Rb1显示出作为喘治疗剂的潜力.
相关概念视频
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
GPCRs Regulate Adenylyl Cylase Activity
7.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K


